Acrux Limited Stock Net Income
| ARUXF Stock | USD 0 0.00 0.00% |
As of the 10th of February, Acrux shows the Risk Adjusted Performance of 0.0667, standard deviation of 30.31, and Mean Deviation of 8.96. Acrux Limited technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acrux Limited risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis to decide if Acrux Limited is priced correctly, providing market reflects its regular price of 0.0045 per share. As Acrux Limited appears to be a penny stock we also recommend to validate its information ratio numbers.
Acrux's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acrux's valuation are provided below:Acrux Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Acrux |
Acrux 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acrux's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acrux.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Acrux on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Acrux Limited or generate 0.0% return on investment in Acrux over 90 days. Acrux is related to or competes with Zelira Therapeutics, and Sigyn Therapeutics. Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Austra... More
Acrux Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acrux's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acrux Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0678 | |||
| Maximum Drawdown | 272.22 |
Acrux Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acrux's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acrux's standard deviation. In reality, there are many statistical measures that can use Acrux historical prices to predict the future Acrux's volatility.| Risk Adjusted Performance | 0.0667 | |||
| Jensen Alpha | 2.14 | |||
| Total Risk Alpha | (1.19) | |||
| Treynor Ratio | 62.12 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acrux's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acrux February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0667 | |||
| Market Risk Adjusted Performance | 62.13 | |||
| Mean Deviation | 8.96 | |||
| Coefficient Of Variation | 1407.68 | |||
| Standard Deviation | 30.31 | |||
| Variance | 918.7 | |||
| Information Ratio | 0.0678 | |||
| Jensen Alpha | 2.14 | |||
| Total Risk Alpha | (1.19) | |||
| Treynor Ratio | 62.12 | |||
| Maximum Drawdown | 272.22 | |||
| Skewness | 4.52 | |||
| Kurtosis | 30.38 |
Acrux Limited Backtested Returns
Acrux is out of control given 3 months investment horizon. Acrux Limited secures Sharpe Ratio (or Efficiency) of 0.0745, which signifies that the company had a 0.0745 % return per unit of risk over the last 3 months. We have analyzed and interpolated sixteen different technical indicators, which can help you to evaluate if expected returns of 2.37% are justified by taking the suggested risk. Use Acrux Standard Deviation of 30.31, risk adjusted performance of 0.0667, and Mean Deviation of 8.96 to evaluate company specific risk that cannot be diversified away. Acrux holds a performance score of 5 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0345, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Acrux's returns are expected to increase less than the market. However, during the bear market, the loss of holding Acrux is expected to be smaller as well. Use Acrux information ratio and rate of daily change , to analyze future returns on Acrux.
Auto-correlation | 0.00 |
No correlation between past and present
Acrux Limited has no correlation between past and present. Overlapping area represents the amount of predictability between Acrux time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acrux Limited price movement. The serial correlation of 0.0 indicates that just 0.0% of current Acrux price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Acrux Limited reported net income of (9.83 Million). This is 102.88% lower than that of the Healthcare sector and 114.04% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.72% higher than that of the company.
Acrux Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acrux's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Acrux could also be used in its relative valuation, which is a method of valuing Acrux by comparing valuation metrics of similar companies.Acrux is currently under evaluation in net income category among its peers.
Acrux Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.43 | |||
| Operating Margin | (7.54) % | |||
| Current Valuation | 11.43 M | |||
| Shares Outstanding | 286.39 M | |||
| Shares Owned By Insiders | 15.17 % | |||
| Shares Owned By Institutions | 14.94 % | |||
| Price To Earning | (218.00) X | |||
| Price To Book | 2.72 X | |||
| Price To Sales | 9.75 X | |||
| Revenue | 1.72 M | |||
| Gross Profit | (4.65 M) | |||
| EBITDA | (12.31 M) | |||
| Net Income | (9.83 M) | |||
| Cash And Equivalents | 5.83 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 2.08 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 3.02 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (8.82 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 18 | |||
| Beta | 1.04 | |||
| Market Capitalization | 13.66 M | |||
| Total Asset | 14.3 M | |||
| Retained Earnings | (53 M) | |||
| Working Capital | 28 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 6 M | |||
| Z Score | 0.6 | |||
| Net Asset | 14.3 M |
About Acrux Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acrux Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrux using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrux Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Acrux Pink Sheet
Acrux financial ratios help investors to determine whether Acrux Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Acrux with respect to the benefits of owning Acrux security.